Current Clinical Trials

Breast Cancer Clinical Trials:

BCCR: Breast Cancer Collaborative Registry (Non-treatment study)

EA1181: (CompassHER2 pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

ML43171: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus In Patients With Estrogen Receptor-Positive, Her2- Negative, Locally Advanced Or Metastatic Breast Cancer

GI Cancer Clinical Trials:

NRG GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

GYN Cancer Clinical Trials:

NRG GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Lung Cancer Clinical Trials:

Alliance A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

A151216: (ALCHEMIST) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

ECOG E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs. Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Pragmatica – Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Supportive Care Clinical Trials:

S2013: “Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study” (NCT# 04871542)

A212102: “Blinded Reference Set for Multicancer Early Detection Blood Tests”

TCBIO-001-0710: The Caris Biorepository Research Protocol

Website for all clinical trials:

For more information about ongoing clinical trials at the William E. Kahlert Regional Cancer Center, please contact the oncology research team:

Brittany Layfield, RN, BSN – Oncology Research Nurse – or 410-871-7487

Jean Marks, RN – Oncology Research Nurse – or 410-871-8393